Loading
x
This site uses cookies

- of Google Analytics
- to remember user login details (encrypted, 10 years)
- and a PHPSESSID cookie to store user location

The PHPSESSID cookie has allready been stored because it does not require consent only notification
The PHPSESSID cookies will automatically be destoyed when closing browser.
By closing this notification cookies are not being set

Cookie Policy for Slzii.com

This is the Cookie Policy for Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact


(0)
| Login | Register | Forgot password?
slzii.com
=>
5
=>
5
=>
6
7
News News
file:nd

Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors

ID: 55644
description:
CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), and is currently undergoing Phase I/II clinical trials in China for the treatment of solid tumors. This milestone marks another breakthrough in Keymed's ADC drug development, further strengthening its innovative therapeutic pipeline in oncology. CM518D1: a novel ADC drug targeting CDH17 CDH17 (Cadherin-17), a member of the cadherin superfamily, is an emerging therapeutic target in gastrointestinal cancers. Studies indicate that CDH17 is highly expressed in multiple gastrointestinal cancers including colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, and plays a critical role in tumor invasion and metastasis. CM518D1 delivers cytotoxic payloads precisely to tumor cells by a CDH17-specific monoclonal antibody, which combines the specificity of antibodies and the potent cytotoxicity of chemotherapeutics. Preclinical studies demonstrated that CM518D1 exhibits strong direct cytotoxic activity, potent bystander killing effect and excellent plasma stability. CM518D1 exhibits remarkable anti-tumor efficacy in multiple solid tumor xenograft models and a favorable safety profile and wide therapeutic window in toxicological evaluations. Clinical development: providing a potential treatment regimen for gastrointestinal cancers Keymed is currently conducting Phase I/II clinical trials in China to evaluate the safety, tolerability, and preliminary efficacy of CM518D1 in patients with advanced solid tumors. Future studies aim to provide a more precise, effective, and safe therapeutic option for patients worldwide with gastrointestinal cancers. Keymed's ADC platform: a next-generation of proprietary ADC program for innovative drug development Keymed's proprietary ADC platform has capabilities for developing next-generation ADCs with novel payloads (e.g., diverse mechanisms of action), hydrophilic linkers (optimized for stability and drug release) and engineered antibodies (enhanced binding and pharmacokinetics). To meet the demands of next-generation ADC development and clinical research, Keymed has established GMP-compliant facilities for linker-payload and ADC drug substance production. This infrastructure positions Keymed at the forefront of ADC therapeutic development, helping to address unmet medical needs for patients worldwide. About Keymed Biosciences Keymed Biosciences Inc. (HKEX: 02162) is a biotech company focused on the urgent unmet clinical needs, and committed to providing high-quality, affordable, innovative therapies for patients in China and overseas. Keymed was founded by medical and scientific experts who have strong experience in the transformation of scientific and technological achievements to commercialization at home and abroad.
Publication date:
2025-04-25 09:44:00
Source ID:
en_prnasisa
Article ID:
2d7375186d8cd920ddafea4b5eae9333
Link:
Video url:
Country (The country of the publisher):
Tajikistan (tajikistan (tj))
Bahrain (bahrain (bh))
Macau (macau (mo))
Turkmenistan (turkmenistan (tm))
Uzbekistan (uzbekistan (uz))
Azerbaijan (azerbaijan (az))
Vietnam (vietnam (vn))
Bangladesh (bangladesh (bd))
Timor-Leste (timor-leste (tl))
Laos (laos (la))
Romania (romania (ro))
Hong Kong (hong kong (hk))
Philippines (philippines (ph))
Qatar (qatar (qa))
Armenia (armenia (am))
Turkey (turkey (tr))
Bhutan (bhutan (bt))
Syria (syria (sy))
Brunei (brunei (bn))
Pakistan (pakistan (pk))
Taiwan (taiwan (tw))
China (china (cn))
United Arab Emirates (united arab emirates (ae))
Saudi Arabia (saudi arabia (sa))
Singapore (singapore (sg))
India (india (in))
Afghanistan (afghanistan (af))
Yemen (yemen (ye))
Language (The language of the news article):
english ()
    Category(s):
    Top
    Keywords:
    mtc
    bio
    hea
    tri
    pha

    Comment

    news last update

    Lesotho 6 Months Ago
    Suriname 6 Months Ago
    Trinidad and Tobago 6 Months Ago
    French Polynesia 6 Months Ago
    San Marino 6 Months Ago
    Fiji 6 Months Ago
    Réunion Island 6 Months Ago
    Jersey 6 Months Ago
    Antigua and Barbuda 6 Months Ago
    Papua New Guinea 6 Months Ago

    newsdata last update

    Costa Rica 2 Hours Ago
    Bolivia 4 Hours Ago
    Sint Maarten 6 Hours Ago
    Cuba 8 Hours Ago
    Peru 10 Hours Ago
    Puerto Rico 12 Hours Ago
    Ecuador 14 Hours Ago
    Chile 16 Hours Ago
    Uruguay 18 Hours Ago
    Argentina 20 Hours Ago

    Social Network News Live now

    x

    0.7482168674469
    Title:News
    title_before: News
    Desc: News
    keyword: News